Tioma Therapeutics
Latest round
- Series A
Last raised
- Aug 2016
Total raised
- $86M
Investors
- 4
About Tioma Therapeutics
Based in the US, Tioma Therapeutics, formerly known as Vasculox, focuses on immuno-oncology and developing anti-CD47 antibodies to treat solid and hematologic cancers. The company was founded by William Frazier, a professor of Biochemistry, Molecular Biophysics, Cell Biology, and Biomedical Engineering at Washington University School of Medicine. John Donovan is the president and CEO of the company.
Who invested in Tioma Therapeutics
4 investors across 1 round
See all investors in Tioma Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 16, 2016
Amount
$86M
Investors
Questions about Tioma Therapeutics
Who invested in Tioma Therapeutics?
Tioma Therapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tioma Therapeutics raised?
Tioma Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Tioma Therapeutics last raise money?
Tioma Therapeutics's most recent round on record is a Series A, in Aug 2016.
What does Tioma Therapeutics do?
Based in the US, Tioma Therapeutics, formerly known as Vasculox, focuses on immuno-oncology and developing anti-CD47 antibodies to treat solid and hematologic cancers.
Where is Tioma Therapeutics headquartered?
Tioma Therapeutics is headquartered in St. Louis, US.
Which VCs invest in companies like Tioma Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Tioma Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Tioma Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.